Moderna, Thermo Fisher Join Forces To Manufacture COVID-19 Vaccine, Other Drugs


Moderna Inc MRNA has entered into a long-term agreement with Thermo Fisher Scientific Inc TMO to manufacture its COVID-19 vaccine and other experimental medicines based on mRNA technology.

  • Thermo Fisher had already partnered with Moderna last year to help scale up production of its COVID vaccine, Spikevax.
  • As a part of the 15-year expanded deal, Thermo Fisher would provide dedicated manufacturing capacity in the U.S. for fill/finish services and labeling and packaging services for Spikevax and other mRNA drugs in Moderna's pipeline.
  • Moderna last week said it was developing three new vaccines based on the same messenger RNA (mRNA) technology used for its COVID-19 shot, including one for viral infection shingles. 
  • On Tuesday, Moderna also announced a partnership with Adium Pharma S.A. to distribute its COVID-19 vaccine in Latin America.
  • Price Action: TMO shares are up 1.08% at $535.60, MRNA stock is down 5.77% at $136.60 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareContractsGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!